Concomitant chemoradiotherapy for treatment of non-small cell lung cancer - the Conrad study

A randomised, multicentre phase III trial of combination chemotherapy +/- thoracic radiotherapy in the treatment of patients with stage III non-small cell lung cancer not eligible for radical therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN63778716

Enrollment

352

Registered

2009-05-29

Start date

2006-11-15

Completion date

Unknown

Last updated

2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer Cancer Malignant neoplasm of bronchus and lung

Interventions

The participants will be randomised to the following two arms: Arm 1: Chemotherapy and thoracic radiation Arm 2: Chemotherapy alone Chemotherapy:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Chemo-naive patients with non-small cell lung cancer (NSCLC) locally advanced stage III, not candidates for radical radiotherapy and with no pleural effusion 2. Performance status (World Health Organization [WHO]) 0 - 2 3. Ability to understand oral and written study information 4. Both males and females, no age limit 5. S-creatinine less than 1.5 times upper reference limit, bilirubin and S-transaminase levels less than 2 times upper limits. Normal white blood-cell and platelet count.

Exclusion criteria

Exclusion criteria: 1. Other active malignancies 2. Pregnancy or breast feeding

Design outcomes

Primary

Measure	Time frame
Overall survival, followed-up for 52 weeks.	—

Secondary

Measure	Time frame
1. Health related quality of life, assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) version 3.0 and the lung cancer specific module EORTC QLQ-LC13. The questionnaires will be sent to the patients every month during the treatment period and every second month after the treatment period for a total of 10 questionnaires completed per patient. 2. Time to progression, followed-up for 52 weeks 3. In field relapse, followed-up for 52 weeks 4. Drug related adverse event frequency and severity, followed-up for 52 weeks 5. Health economics, followed-up for 52 weeks	—

Measure

Time frame

1. Health related quality of life, assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) version 3.0 and the lung cancer specific module EORTC QLQ-LC13. The questionnaires will be sent to the patients every month during the treatment period and every second month after the treatment period for a total of 10 questionnaires completed per patient. 2. Time to progression, followed-up for 52 weeks 3. In field relapse, followed-up for 52 weeks 4. Drug related adverse event frequency and severity, followed-up for 52 weeks 5. Health economics, followed-up for 52 weeks

—

Countries

Norway

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026